Literature DB >> 28748634

Timing of births and oral contraceptive use influences ovarian cancer risk.

Anna H Wu1, Celeste Leigh Pearce1,2, Alice W Lee3, Chiuchen Tseng1, Anjali Jotwani4, Prusha Patel4, Malcolm C Pike1,4.   

Abstract

Increasing parity and duration of combined oral contraceptive (COC) use provide substantial protection against ovarian carcinoma (cancer). There are limited data on the impact of the age of the births or age of COC use on reducing ovarian cancer risk. Here, we examined the effects of age at first and last births and age at use of COCs using data from studies conducted in Los Angeles County, California, USA (1,632 cases, 2,340 controls). After adjusting for the number of births, every 5 years that a first birth was delayed reduced the risk of ovarian cancer by 13% (95% CI 5-21%; p = 0.003); a first birth after age 35 was associated with a 47% lower risk than a first birth before age 25. COC use before age 35 was associated with greater protection per year of use than COC use at older ages. Considering previously published results as well as the results presented here, increasing parity and a later age at births are both important protective factors against ovarian cancer and the protection extends over 30 or more years from last birth. Current models of the etiology of ovarian cancer do not encompass an effect of late age at births. Our result of an attenuation of the protective effect with COC use after around age 35 needs further investigation as it has not been seen in all studies.
© 2017 UICC.

Entities:  

Keywords:  oral contraceptives; ovarian cancer; parity

Mesh:

Substances:

Year:  2017        PMID: 28748634      PMCID: PMC7560976          DOI: 10.1002/ijc.30910

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.

Authors:  K Yost; C Perkins; R Cohen; C Morris; W Wright
Journal:  Cancer Causes Control       Date:  2001-10       Impact factor: 2.506

2.  Timing of pregnancy and the risk of epithelial ovarian cancer.

Authors:  David C Whiteman; Victor Siskind; David M Purdie; Adèle C Green
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-01       Impact factor: 4.254

3.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies.

Authors: 
Journal:  Lancet       Date:  1996-06-22       Impact factor: 79.321

4.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.

Authors:  V Beral; R Doll; C Hermon; R Peto; G Reeves
Journal:  Lancet       Date:  2008-01-26       Impact factor: 79.321

5.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group.

Authors:  A S Whittemore; R Harris; J Itnyre
Journal:  Am J Epidemiol       Date:  1992-11-15       Impact factor: 4.897

6.  Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study.

Authors:  Malcolm C Pike; Celeste L Pearce; Ruth Peters; Wendy Cozen; Peggy Wan; Anna H Wu
Journal:  Fertil Steril       Date:  2004-07       Impact factor: 7.329

7.  Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women.

Authors:  Patricia G Moorman; Brian Calingaert; Rachel T Palmieri; Edwin S Iversen; Rex C Bentley; Susan Halabi; Andrew Berchuck; Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2008-02-25       Impact factor: 4.897

8.  Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study.

Authors:  Tomas Riman; Paul W Dickman; Staffan Nilsson; Nestor Correia; Hans Nordlinder; Cecilia M Magnusson; Ingemar R Persson
Journal:  Am J Epidemiol       Date:  2002-08-15       Impact factor: 4.897

9.  Menstrual and reproductive factors in relation to ovarian cancer risk.

Authors:  L Titus-Ernstoff; K Perez; D W Cramer; B L Harlow; J A Baron; E R Greenberg
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

10.  Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer.

Authors:  Celeste Leigh Pearce; Mary Anne Rossing; Alice W Lee; Roberta B Ness; Penelope M Webb; Georgia Chenevix-Trench; Susan M Jordan; Douglas A Stram; Jenny Chang-Claude; Rebecca Hein; Stefan Nickels; Galina Lurie; Pamela J Thompson; Michael E Carney; Marc T Goodman; Kirsten Moysich; Estrid Hogdall; Allan Jensen; Ellen L Goode; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Rachel Palmieri Weber; Argyrios Ziogas; Hoda Anton-Culver; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Louise Brinton; Nicolas Wentzensen; Jolanta Lissowska; Montserrat Garcia-Closas; Leon F A G Massuger; Lambertus A L M Kiemeney; Anne M Van Altena; Katja K H Aben; Andrew Berchuck; Jennifer A Doherty; Edwin Iversen; Valerie McGuire; Patricia G Moorman; Paul Pharoah; Malcolm C Pike; Harvey Risch; Weiva Sieh; Daniel O Stram; Kathryn L Terry; Alice Whittemore; Anna H Wu; Joellen M Schildkraut; Susanne K Kjaer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-05       Impact factor: 4.254

View more
  10 in total

1.  Preterm delivery is associated with an increased risk of epithelial ovarian cancer among parous women.

Authors:  Camilla Sköld; Tone Bjørge; Anders Ekbom; Anders Engeland; Mika Gissler; Tom Grotmol; Laura Madanat-Harjuoja; Anne Gulbech Ording; Olof Stephansson; Britton Trabert; Steinar Tretli; Rebecca Troisi; Henrik Toft Sørensen; Ingrid Glimelius
Journal:  Int J Cancer       Date:  2018-07-10       Impact factor: 7.396

2.  Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

Authors:  Frank G Lawton; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-03-24

3.  Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.

Authors:  Lilah Khoja; Rachel Palmieri Weber; Penelope M Webb; Susan J Jordan; Aruna Muthukumar; Jenny Chang-Claude; Renée T Fortner; Allan Jensen; Susanne K Kjaer; Harvey Risch; Jennifer Anne Doherty; Holly R Harris; Marc T Goodman; Francesmary Modugno; Kirsten Moysich; Andrew Berchuck; Joellen M Schildkraut; Daniel Cramer; Kathryn L Terry; Hoda Anton-Culver; Argyrios Ziogas; Minh Tung Phung; Gillian E Hanley; Anna H Wu; Bhramar Mukherjee; Karen McLean; Kathleen Cho; Malcolm C Pike; Celeste Leigh Pearce; Alice W Lee
Journal:  Gynecol Oncol       Date:  2021-11-12       Impact factor: 5.304

4.  Intrauterine device use and risk of ovarian cancer: Results from the New England Case-Control study and Nurses' Health Studies.

Authors:  Jiaxi Yang; Naoko Sasamoto; Ana Babic; Allison F Vitonis; Mary K Townsend; Linda Titus; Daniel W Cramer; Shelley S Tworoger; Kathryn L Terry
Journal:  Int J Cancer       Date:  2021-03-17       Impact factor: 7.316

5.  Sleep duration and the risk of cancer: a systematic review and meta-analysis including dose-response relationship.

Authors:  Yuheng Chen; Fengwei Tan; Luopei Wei; Xin Li; Zhangyan Lyu; Xiaoshuang Feng; Yan Wen; Lanwei Guo; Jie He; Min Dai; Ni Li
Journal:  BMC Cancer       Date:  2018-11-21       Impact factor: 4.430

6.  Relationship between the precursors of high grade serous ovarian cancer and patient characteristics: decreased incidence of the p53 signature in pregnant women.

Authors:  Tsutomu Ida; Hiroyuki Fujiwara; Takahiro Kiriu; Yoshimi Taniguchi; Akira Kohyama
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

7.  Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.

Authors:  Alice W Lee; Stacey Rosenzweig; Ashley Wiensch; Susan J Ramus; Usha Menon; Aleksandra Gentry-Maharaj; Argyrios Ziogas; Hoda Anton-Culver; Alice S Whittemore; Weiva Sieh; Joseph H Rothstein; Valerie McGuire; Nicolas Wentzensen; Elisa V Bandera; Bo Qin; Kathryn L Terry; Daniel W Cramer; Linda Titus; Joellen M Schildkraut; Andrew Berchuck; Ellen L Goode; Susanne K Kjaer; Allan Jensen; Susan J Jordan; Roberta B Ness; Francesmary Modugno; Kirsten Moysich; Pamela J Thompson; Marc T Goodman; Michael E Carney; Jenny Chang-Claude; Mary Anne Rossing; Holly R Harris; Jennifer Anne Doherty; Harvey A Risch; Lilah Khoja; Aliya Alimujiang; Minh Tung Phung; Katharine Brieger; Bhramar Mukherjee; Paul D P Pharoah; Anna H Wu; Malcolm C Pike; Penelope M Webb; Celeste Leigh Pearce
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

8.  Association Between Breastfeeding and Ovarian Cancer Risk.

Authors:  Ana Babic; Naoko Sasamoto; Bernard A Rosner; Shelley S Tworoger; Susan J Jordan; Harvey A Risch; Holly R Harris; Mary Anne Rossing; Jennifer A Doherty; Renée T Fortner; Jenny Chang-Claude; Marc T Goodman; Pamela J Thompson; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Allan Jensen; Joellen M Schildkraut; Linda J Titus; Daniel W Cramer; Elisa V Bandera; Bo Qin; Weiva Sieh; Valerie McGuire; Rebecca Sutphen; Celeste L Pearce; Anna H Wu; Malcolm Pike; Penelope M Webb; Francesmary Modugno; Kathryn L Terry
Journal:  JAMA Oncol       Date:  2020-06-11       Impact factor: 33.006

9.  Age at last birth and risk of developing epithelial ovarian cancer: a meta-analysis.

Authors:  Yanjun Wu; Wenjun Sun; Xueling Xin; Weijing Wang; Dongfeng Zhang
Journal:  Biosci Rep       Date:  2019-09-13       Impact factor: 3.840

10.  Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study.

Authors:  Frida E Lundberg; Anna L V Johansson; Kenny Rodriguez-Wallberg; Kristina Gemzell-Danielsson; Anastasia N Iliadou
Journal:  Eur J Epidemiol       Date:  2019-08-03       Impact factor: 8.082

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.